RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+15.06%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1B
AUM Growth
+$1B
(+7.9%)
Cap. Flow
-$30M
Cap. Flow
% of AUM
-3%
Top 10 Holdings %
Top 10 Hldgs %
34.85%
Holding
100
New
15
Increased
28
Reduced
32
Closed
15
Top Buys
| 1 |
Medtronic
MDT
|
$17.8M |
| 2 |
Thermo Fisher Scientific
TMO
|
$17.5M |
| 3 |
Pfizer
PFE
|
$16.7M |
| 4 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$11.2M |
| 5 |
DexCom
DXCM
|
$8.07M |
Top Sells
| 1 |
Becton Dickinson
BDX
|
$24.6M |
| 2 |
CVS Health
CVS
|
$12.8M |
| 3 |
Eli Lilly
LLY
|
$12.8M |
| 4 |
Elevance Health
ELV
|
$11.8M |
| 5 |
McKesson
MCK
|
$11.6M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cigna
CI
$80.2B
| $14.1M | 1.41% |
47,000
-33,000
| -41% | -$9.88M |
|
|
AXNX
27
DELISTED
Axonics, Inc. Common Stock
AXNX
| $13.7M | 1.37% |
220,000
-10,000
| -4% | -$622K |
|
|
28
DexCom
DXCM
$30.9B
| $13.6M | 1.36% |
110,000
+65,000
| +144% | +$8.07M |
|
29
Procept Biorobotics
PRCT
$2.11B
| $13M | 1.3% |
310,000
-183,000
| -37% | -$7.67M |
|
30
Cytokinetics
CYTK
$5.98B
| $12.5M | 1.25% |
149,912
-50,088
| -25% | -$4.18M |
|
31
Exact Sciences
EXAS
$9.33B
| $12.2M | 1.22% |
165,000
+5,000
| +3% | +$370K |
|
32
Royalty Pharma
RPRX
$15.8B
| $12.1M | 1.21% |
429,697
+279,697
| +186% | +$7.86M |
|
33
Dynavax Technologies
DVAX
$1.19B
| $11.2M | 1.12% |
800,000
+100,000
| +14% | +$1.4M |
|
34
Oscar Health
OSCR
$4.57B
| $10.9M | 1.09% |
1,192,054
+422,054
| +55% | +$3.86M |
|
|
35
CVS Health
CVS
$93B
| $10.9M | 1.08% |
137,500
-162,500
| -54% | -$12.8M |
|
36
Privia Health
PRVA
$2.84B
| $10.6M | 1.06% |
460,000
| – | – |
|
37
IQVIA
IQV
$31.4B
| $10.4M | 1.04% |
45,000
-2,000
| -4% | -$463K |
|
38
Centene
CNC
$14.8B
| $10M | 1% |
135,000
+105,000
| +350% | +$7.79M |
|
39
Glaukos
GKOS
$5.42B
| $9.54M | 0.95% |
120,000
+47,000
| +64% | +$3.74M |
|
40
Alkermes
ALKS
$4.95B
| $9.43M | 0.94% |
340,000
-30,000
| -8% | -$832K |
|
41
Iovance Biotherapeutics
IOVA
$800M
| $9.08M | 0.91% |
1,116,818
+166,818
| +18% | +$1.36M |
|
42
Charles River Laboratories
CRL
$7.99B
| $8.98M | 0.9% |
38,000
-6,000
| -14% | -$1.42M |
|
43
Nuvalent
NUVL
$5.74B
| $8.31M | 0.83% |
112,929
+26,918
| +31% | +$1.98M |
|
44
Alignment Healthcare
ALHC
$3.23B
| $8.18M | 0.82% |
950,000
-250,000
| -21% | -$2.15M |
|
45
Neurocrine Biosciences
NBIX
$13.5B
| $8.17M | 0.82% |
62,000
+7,434
| +14% | +$980K |
|
46
Evolent Health
EVH
$1.11B
| $7.6M | 0.76% |
230,000
+85,000
| +59% | +$2.81M |
|
47
Align Technology
ALGN
$9.59B
| $7.4M | 0.74% |
+27,000
| New | +$7.4M |
|
48
Alnylam Pharmaceuticals
ALNY
$58.6B
| $7.18M | 0.72% |
37,500
-7,500
| -17% | -$1.44M |
|
49
Zimmer Biomet
ZBH
$20.8B
| $6.69M | 0.67% |
55,000
-5,000
| -8% | -$609K |
|
50
Avantor
AVTR
$8.74B
| $6.67M | 0.67% |
+292,000
| New | +$6.67M |
|